Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 1
2000 2
2002 6
2003 5
2004 3
2005 4
2006 2
2007 5
2008 9
2009 7
2010 20
2011 24
2012 17
2013 19
2014 11
2015 25
2016 16
2017 21
2018 16
2019 13
2020 19
2021 14
2022 18
2023 20
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Results by year

Filters applied: . Clear all
Page 1
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, Foldyna B, Looby SE, Desvigne-Nickens P, Alston-Smith B, Leon-Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaudo HJ, Douglas PS; REPRIEVE Investigators. Grinspoon SK, et al. N Engl J Med. 2023 Aug 24;389(8):687-699. doi: 10.1056/NEJMoa2304146. Epub 2023 Jul 23. N Engl J Med. 2023. PMID: 37486775 Free PMC article. Clinical Trial.
The trial was stopped early for efficacy after a median follow-up of 5.1 years (interquartile range, 4.3 to 5.9). The incidence of a major adverse cardiovascular event was 4.81 per 1000 person-years in the pitavastatin group and 7.32 per 1000 person-years in the pla …
The trial was stopped early for efficacy after a median follow-up of 5.1 years (interquartile range, 4.3 to 5.9). The incidence of a major …
Hydrophilic or Lipophilic Statins?
Climent E, Benaiges D, Pedro-Botet J. Climent E, et al. Front Cardiovasc Med. 2021 May 20;8:687585. doi: 10.3389/fcvm.2021.687585. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34095267 Free PMC article. Review.
The predominantly lipophilic statins (simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin) can easily enter cells, whereas hydrophilic statins (rosuvastatin and pravastatin) present greater hepatoselectivity. ...Thus, the aim of the present review was to co …
The predominantly lipophilic statins (simvastatin, fluvastatin, pitavastatin, lovastatin and atorvastatin) can easily enter cells, wh …
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases.
Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, You SC, Park RW, Park YM, Kim KJ, Rhee SY, Park M, Jin ES, Kim SE. Seo WW, et al. Cardiovasc Diabetol. 2022 May 23;21(1):82. doi: 10.1186/s12933-022-01524-6. Cardiovasc Diabetol. 2022. PMID: 35606846 Free PMC article.
The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin + rosuvastatin (HR 0.72; 95% CI 0.59-0.87). ...A consistently low risk of NODM in pitavastatin users was observed when compared with low-to …
The meta-analysis of the HRs demonstrated that pitavastatin resulted in a significantly reduced risk of NODM than atorvastatin + rosu …
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. Taguchi I, et al. Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615. Circulation. 2018. PMID: 29735587 Free PMC article. Clinical Trial.
METHODS: In this prospective, multicenter, randomized, open-label, blinded end point study, 13 054 Japanese patients with stable coronary artery disease who achieved low-density lipoprotein cholesterol (LDL-C) <120 mg/dL during a run-in period (pitavastatin 1 mg/d) were …
METHODS: In this prospective, multicenter, randomized, open-label, blinded end point study, 13 054 Japanese patients with stable coronary ar …
An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins.
Hirota T, Fujita Y, Ieiri I. Hirota T, et al. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):809-822. doi: 10.1080/17425255.2020.1801634. Epub 2020 Aug 6. Expert Opin Drug Metab Toxicol. 2020. PMID: 32729746 Review.
EXPERT OPINION: Understanding the mechanisms underlying statin interactions can help minimize drug interactions and reduce the adverse side effects caused by statins. Since recent studies have shown the involvement of drug transporters such as OATP and BCRP as well …
EXPERT OPINION: Understanding the mechanisms underlying statin interactions can help minimize drug interactions and reduce the adverse …
Pitavastatin: an overview.
Saito Y. Saito Y. Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8. Atheroscler Suppl. 2011. PMID: 22152281 Review.
In addition to its potent LDL-C-lowering efficacy, a number of pleiotropic benefits that might lead to a reduction in residual risk have been suggested in vitro. These include beneficial effects on endothelial function, stabilisation of the coronary plaque, anti-inflammato …
In addition to its potent LDL-C-lowering efficacy, a number of pleiotropic benefits that might lead to a reduction in residual risk have bee …
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. Cooper-DeHoff RM, et al. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. Clin Pharmacol Ther. 2022. PMID: 35152405 Free PMC article.
There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ...Geneti …
There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B …
Pitavastatin: A Review in Hypercholesterolemia.
Hoy SM. Hoy SM. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168. doi: 10.1007/s40256-017-0213-8. Am J Cardiovasc Drugs. 2017. PMID: 28130659 Review.
Oral pitavastatin (Livalo(); Livazo()) is a competitive HMG-CoA reductase inhibitor that is available in the EU for the reduction of elevated total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels in adults with primary hypercholesterolemia and combined ( …
Oral pitavastatin (Livalo(); Livazo()) is a competitive HMG-CoA reductase inhibitor that is available in the EU for the reduction of …
Pitavastatin and carbohydrate metabolism: what is the evidence?
Filippatos TD, Elisaf MS. Filippatos TD, et al. Expert Rev Clin Pharmacol. 2016 Jul;9(7):955-60. doi: 10.1586/17512433.2016.1165607. Epub 2016 Mar 28. Expert Rev Clin Pharmacol. 2016. PMID: 26967972 Review.
Clinical and experimental evidence shows that pitavastatin increases adiponectin levels and reduces oxidative stress, effects that seem to be implicated in the beneficial effect of the drug on carbohydrate metabolism variables. Pitavastatin is a useful hypoli …
Clinical and experimental evidence shows that pitavastatin increases adiponectin levels and reduces oxidative stress, effects …
Pitavastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Wright JM. Adams SP, et al. Cochrane Database Syst Rev. 2020 Jun 19;6(6):CD012735. doi: 10.1002/14651858.CD012735.pub2. Cochrane Database Syst Rev. 2020. PMID: 32557581 Free PMC article.
To compare the effect of pitavastatin on surrogate markers with other statins. Secondary objectives To quantify the effect of various doses of pitavastatin on withdrawals due to adverse effects. ...There were not enough data to determine risk of withdr …
To compare the effect of pitavastatin on surrogate markers with other statins. Secondary objectives To quantify the effect of various …
275 results